Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.
Marta Trigo-RodríguezSheila CárcelAna NavasReinaldo Espíndola-GómezJosé Carlos Garrido-GraciaMaría Ángeles Esteban MorenoRafael León-LópezPedro María Martínez Pérez-CrespoEduardo Aguilar AlonsoDavid Vinuesa GarcíaAlberto RomeroInés Pérez CamachoBelén Gutiérrez GutiérrezFrancisco Javier Martínez-MarcosConcepción Fernández-RoldánEva LeónAlexandra Aceituno CañoJuan E Corzo-DelgadoElena Perez-NadalesCristina RiazzoCarmen de la FuenteAurora Jurado RogerJulian Torre-CisnerosNicolás MerchantePublished in: Open forum infectious diseases (2023)
IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.